Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets

被引:176
|
作者
Misra, Durga Prasanna [1 ]
Agarwal, Vikas [1 ]
Gasparyan, Armen Yuri [2 ]
Zimba, Olena [3 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol & Rheumatol, Lucknow, Uttar Pradesh, India
[2] Dudley Grp NHS Fdn Trust Teaching Trust, Dept Rheumatol & Res & Dev, Russells Hall Hosp, Dudley, W Midlands, England
[3] Danylo Halytsky Lviv Natl Med Univ, Dept Internal Med 2, Lvov, Ukraine
关键词
COVID-19; Epidemiology; Hydroxychloroquine; Hypothesis; Immunity; Pathogenesis; Vaccines; Vitamin D; 2019-NCOV; PNEUMONIA; KOREA;
D O I
10.1007/s10067-020-05073-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.
引用
收藏
页码:2055 / 2062
页数:8
相关论文
共 50 条
  • [41] Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets
    Ruenjaiman, Vichaya
    Hirankarn, Nattiya
    Palaga, Tanapat
    [J]. ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2021, 39 (02): : 69 - 77
  • [42] Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
    Kawazoe, Mai
    Kihara, Mari
    Nanki, Toshihiro
    [J]. PHARMACEUTICALS, 2021, 14 (12)
  • [43] What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?
    Guterres, Alexandro
    de Azeredo Lima, Carlos Henrique
    Miranda, Renan Lyra
    Gadelha, Monica Roberto
    [J]. INFECTION GENETICS AND EVOLUTION, 2020, 85
  • [44] Management and Perspective of Coronavirus Disease 2019 (COVID-19), Pregnancy, and Hypercoagulability
    Umair Nasir
    Sarfraz Ahmad
    [J]. SN Comprehensive Clinical Medicine, 2021, 3 (5) : 1081 - 1084
  • [45] Telemedicine in the Era of Coronavirus Disease 2019 (COVID-19): A Neurosurgical Perspective
    Blue, Rachel
    Yang, Andrew, I
    Zhou, Cecilia
    De Ravin, Emma
    Teng, Clare W.
    Arguelles, Gabriel R.
    Huang, Vincent
    Wathen, Connor
    Miranda, Stephen P.
    Marcotte, Paul
    Malhotra, Neil R.
    Welch, William C.
    Lee, John Y. K.
    [J]. WORLD NEUROSURGERY, 2020, 139 : 549 - 557
  • [46] An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19)
    Das, Saibal
    Bhowmick, Subhrojyoti
    Tiwari, Sayali
    Sen, Sukanta
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (07) : 591 - 601
  • [47] COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease
    Dousari, Amin Sadeghi
    Moghadam, Majid Taati
    Satarzadeh, Naghmeh
    [J]. INFECTION AND DRUG RESISTANCE, 2020, 13 : 2819 - 2828
  • [48] An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19)
    Saibal Das
    Subhrojyoti Bhowmick
    Sayali Tiwari
    Sukanta Sen
    [J]. Clinical Drug Investigation, 2020, 40 : 591 - 601
  • [49] Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19
    Sell, Stacy L.
    Prough, Donald S.
    Weisz, Harris A.
    Widen, Steve G.
    Hellmich, Helen L.
    [J]. PLOS ONE, 2021, 16 (09):
  • [50] COVID-19: Physiopathology and Targets for Therapeutic Intervention
    de Almeida, Juliana O.
    de Oliveira, Victoria Regina T.
    Avelar, Joao Lucas dos S.
    Moita, Bruna Simoes
    Lima, Lidia Moreira
    [J]. REVISTA VIRTUAL DE QUIMICA, 2020, 12 (06) : 1464 - 1497